Shinsei Capital Partners
VC Fund
Tokyo, Japan
Shinsei Capital Partners is a VC fund in Tokyo focused on Health Care and Pharmaceutical. Shinsei Capital Partners invested startup companies engaged in life science such as biotech or digital health technology.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries Shinsei Capital Partners invests in
Stages Shinsei Capital Partners invests in
Countries Shinsei Capital Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $25M–$425M
Investment Focus
Industry
- Health Care 2 (22%)
- Pharmaceutical 2 (22%)
- SNS 1 (11%)
- Android 1 (11%)
- Content 1 (11%)
Stage
- Series B 4 (44%)
- Seed 2 (22%)
- Series A 1 (11%)
- Funding Round 1 (11%)
- Venture - Series Unknown 1 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Manabu Nakamura
Founder, CEO and Managing Partner
|
Founder, CEO and Managing Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| MiddleField is a team to make cars the best entertainment and to make the lives of everyone involved in cars into entertainment. They creates a society where a lot of people are involved as a middle point of all people's dreams. MiddleField owns and operates an e-commerce platform offering cars. | $2.3M / Series B / Oct 13, 2020 | ||
| FunPep is an Industry-university collaboration bioventure company. | $14.1M / Venture - Series Unknown / Aug 14, 2020 | ||
| Financier provides Japan's only Web3 platform aimed at realizing a creator economy that supports the challenges of 1 billion people. The platform enables creators to issue tokens, fostering community engagement and new economic models. By leveraging blockchain technology, it empowers individuals to monetize their influence and buildsustainable communities. | $2.2M / Seed / Apr 30, 2020 | ||
| Mira Robotics is a software based company provide services that can robots in various fields. | $5M / Seed / Jan 15, 2020 | ||
| Through the development of next-generation multifunctional biopharmaceuticals (neobiologics) using technology based on a unique new concept , we will realize our mission, grow as a global company, and contribute to human health care. By developing biopharmaceuticals with new modalities using LassoGraft Technology ® as a core technology, we willwork on solving unmet medical needs, satisfying treatment methods in the field of rare diseases, and proposing solutions to expensive medical problems. | $77.8M / Jan 15, 2020 | ||
| Modalis Therapeutics Corporation is an biotech company focusing on developing transformative therapeutics for unmet medical needs using its proprietary technologies on CRISPR and protein engineering platforms. The company has a strong foundation on intellectual property licensed from the University of Tokyo. | $25M / Series B / Apr 10, 2019 | ||
| AlphaNavi Pharma specializes in the research and development of new drugs. | $8.1M / Series A / Apr 05, 2019 | ||
| Chordia Therapeutics is a research and development type bioventure specializing in oncology field. The company has a mission of delivering new therapeutic drugs to patients as soon as possible in the area of cancer with high unmet medical need. | $26.9M / Series B / Apr 01, 2019 | ||
| Veritas In Silico is a start-up to research and sales of pharmaceuticals.Veritas In Silico, target partial structures in messenger RNA (mRNA) by exploring the true form of RNA, the origin of life, based on in silico (computer-based computational science) technology Established a drug discovery system with a completely new concept.This mRNA-targeteddrug has the potential to be applied to any disease, including those for which it has been difficult to develop therapeutic drugs using conventional protein-based drug discovery. Therefore, it is expected to be a favorite for next-generation drug discovery that will cause a paradigm shift in the pharmaceutical industry. | $7.2M / Series B / Mar 29, 2019 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Shinsei Capital Partners invest in?
Shinsei Capital Partners invests primarily in Health Care, Pharmaceutical and SNS startups, most often at Series B and Seed stage. Most of the 9 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Shinsei Capital Partners's check size?
Shinsei Capital Partners typically joins rounds of $25M–$425M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Shinsei Capital Partners participates in.
How do I contact Shinsei Capital Partners?
Public channels for Shinsei Capital Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Shinsei Capital Partners?
The team at Shinsei Capital Partners includes Manabu Nakamura (Founder, CEO and Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
